Send us Feedback

Orexigen Therapeutics (OREX)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Orexigen(R) Therapeutics to Present at JP Morgan Healthcare Conference
PR Newswire  Jan 7  Comment 
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the JP Morgan Healthcare Conference. The
Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
PR Newswire  Dec 23  Comment 
SAN DIEGO, Dec. 23 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on December 23, 2009 the Compensation Committee of the Company's Board
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire  Nov 24  Comment 
SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of
Four Senior Executives Join Orexigen(R) Therapeutics Management Team
PR Newswire  Nov 23  Comment 
SAN DIEGO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that four senior executives have joined the organization, strengthening the management team that is driving the development of its
Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
PR Newswire  Nov 12  Comment 
SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Lazard Capital Markets 6th Annual
Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
StreetInsider.com  Nov 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Orexigen+%28OREX%29+Reports+Q3+Loss+of+%240.33%2C+Beats+by+3c/5076581.html for the full story.
Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
PR Newswire  Nov 4  Comment 
SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced unaudited financial results for the three months ended September 30, 2009.
Orexigen wows analysts with IIb obesity data
FierceBiotech  Sep 30  Comment 
With its lead obesity drug poised to head to the FDA in search of an approval, Orexigen Therapeutics (OREX) pulled the covers off promising Phase IIb data on a follow-up drug that's now pointed to a late-stage trial. The San Diego-based...
Orexigen Therapeutics (OREX) Announces Statistically Significantly Phase 2b Trial for Empatic
StreetInsider.com  Sep 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Orexigen+Therapeutics+%28OREX%29+Announces+Statistically+Significantly+Phase+2b+Trial+for+Empatic/4980038.html for the full story.
Orexigen Moves Forward With 2nd Obesity Drug: BioBuzz
TheStreet.com  Sep 30  Comment 
A midstage study of Empatic demonstrates significant weight loss.



Thank you for your suggestion
SEC FILINGS
SEC FILINGS  (See all)
10-K (Mar 09)
Older: 03/27/08
10-Q (Nov 09)
Older: 08/07/09, 05/08/09, 11/07/08, 08/08/08
View All Filings for Orexigen_Therapeutics (OREX)
more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 
OREX AT A GLANCE
P/E ►-4.53 
EV/EBITDA ►-5.55 
ROA ►-66.1% 
ROE ►-90.8% 
Debt to Equity ►0.274 
Current Ratio ►6.16 
Interest Coverage Ratio ►-51.4 
 
 
Please install Flash Player to view this chart.
 
 
 
Please install Flash Player to view this chart.
 




References

Retrieved from "http://www.wikinvest.com/stock/Orexigen_Therapeutics_(OREX)"
Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki